Acelyrin, Inc. – NASDAQ:SLRN
Acelyrin stock price today
$2.27
-0.98
-30.15%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Acelyrin stock price monthly change
-42.98%
month
Acelyrin stock price quarterly change
-42.98%
quarter
Acelyrin stock price yearly change
-58.28%
year
Acelyrin key metrics
Market Cap | 311.48M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -2.61 |
Revenue | N/A |
EBITDA | -335.04M |
Income | -240.16M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAcelyrin stock price history
Acelyrin stock forecast
Acelyrin financial statements
Average Price Target
$10.5
Potential upside: 362.55%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -26.03M | |
|---|---|---|---|
| Sep 2023 | 0 | -83.94M | |
| Dec 2023 | 0 | -95.21M | |
| Mar 2024 | 0 | -34.97M |
| 2024-03-26 | -1 | -0.75 |
|---|---|---|
| 2024-03-28 | -1 | -0.75 |
| 2024-05-14 | -0.93 | -0.36 |
| Jun 2023 | 835126000 | 34.06M | 4.08% |
|---|---|---|---|
| Sep 2023 | 800489000 | 1.19B | 149.16% |
| Dec 2023 | 742690000 | 86.35M | 11.63% |
| Mar 2024 | 697484000 | 53.41M | 7.66% |
| Jun 2023 | -31.62M | -267.87M | 566.46M |
|---|---|---|---|
| Sep 2023 | -39.12M | -134.80M | -499K |
| Dec 2023 | -73.63M | -92.60M | 2.59M |
| Mar 2024 | -57.29M | 100.89M | 2.80M |
Acelyrin alternative data
| Dec 2023 | 108 |
|---|---|
| Jan 2024 | 108 |
| Feb 2024 | 108 |
| Mar 2024 | 108 |
| Apr 2024 | 108 |
| May 2024 | 108 |
| Jun 2024 | 135 |
| Jul 2024 | 135 |
Acelyrin other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 10691 |
| Jul 2024 | 0 | 1 |
| Quarter | Transcript |
|---|---|
| Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 16 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Acelyrin stock today?
One share of Acelyrin stock can currently be purchased for approximately $2.27.
-
When is Acelyrin's next earnings date?
Unfortunately, Acelyrin's (SLRN) next earnings date is currently unknown.
-
Does Acelyrin pay dividends?
No, Acelyrin does not pay dividends.
-
How much money does Acelyrin make?
Acelyrin has a market capitalization of 311.48M. Acelyrin made a loss 381.64M US dollars in net income (profit) last year or -$0.36 on an earnings per share basis.
-
What is Acelyrin's stock symbol?
Acelyrin, Inc. is traded on the NASDAQ under the ticker symbol "SLRN".
-
What is Acelyrin's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Acelyrin?
Shares of Acelyrin can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Acelyrin have?
As Jul 2024, Acelyrin employs 135 workers, which is 25% more then previous quarter.
-
When Acelyrin went public?
Acelyrin, Inc. is publicly traded company for more then 2 years since IPO on 4 May 2023.
-
What is Acelyrin's official website?
The official website for Acelyrin is acelyrin.com.
-
Where are Acelyrin's headquarters?
Acelyrin is headquartered at 4149 Liberty Canyon Road, Agoura Hills, CA.
-
How can i contact Acelyrin?
Acelyrin's mailing address is 4149 Liberty Canyon Road, Agoura Hills, CA and company can be reached via phone at 805-730-0360.
-
What is Acelyrin stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Acelyrin in the last 12 months, the avarage price target is $10.5. The average price target represents a 362.55% change from the last price of $2.27.
Acelyrin company profile:
Acelyrin, Inc.
acelyrin.comExchange:
NASDAQ
Full time employees:
135
Industry:
Biotechnology
Sector:
Healthcare
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
4149 Liberty Canyon Road
Agoura Hills, CA 91301
Agoura Hills, CA 91301
CIK: 0001962918
ISIN: US00445A1007
CUSIP: 00445A100
